Pricing Log in Create free account

Novavax, Inc. (NVAX) vs Ultragenyx Pharmaceutical Inc. (RARE)

Novavax, Inc. and Ultragenyx Pharmaceutical Inc. are both Biotechnology companies. Novavax, Inc. and Ultragenyx Pharmaceutical Inc. are of similar size ($1.7B and $1.7B). Ultragenyx Pharmaceutical Inc. grew revenue faster over the last twelve months: 15.8% against −61.3%. Novavax, Inc. has the higher net margin (−18.6% vs −71.7%) and the higher return on invested capital (0.00% vs 0.00%). Across the 16 metrics below, Novavax, Inc. leads on 10 and Ultragenyx Pharmaceutical Inc. on 6.

Valuation

Metric NVAX RARE Biotechnology median
P/E n/m n/m 11.58
P/S 4.00 2.33 9.61
P/B n/m n/m 2.26
Price to free cash flow n/m n/m 26.41
EV/EBITDA n/m n/m 0.72
EV/Sales 3.20 1.97 9.43
Earnings yield (4.61%) (31.13%) (32.28%)
Free cash flow yield (14.93%) (26.27%) (22.27%)

Profitability

Metric NVAX RARE Biotechnology median
Gross margin 78.01% 82.88% 68.81%
Operating margin (21.23%) (63.98%) 0.00%
Net margin (18.64%) (71.72%) 0.00%
Free cash flow margin (59.25%) (61.20%) 0.00%
Return on equity 41.08% 285.46% (50.30%)
Return on assets (7.42%) (44.05%) (45.47%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric NVAX RARE Biotechnology median
Revenue growth (TTM) (61.33%) 15.78% 6.78%
EPS growth (last fiscal year) 309.76% 7.31% 29.88%
Revenue growth, 5-year CAGR 18.76% 19.95% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric NVAX RARE Biotechnology median
Debt to equity (1.35) 0.00 0.00
Current ratio 2.15 1.40 4.74
Net debt to EBITDA (1.04) 1.35 1.01

Dividend

Metric NVAX RARE Biotechnology median
Dividend yield — — 0.39%
Payout ratio — — —

Size

Metric NVAX RARE Biotechnology median
Market cap 1.65b 1.70b 168.63m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack